Search Results - Jean‐Philippe Metges

  • Showing 1 - 16 results of 16
Refine Results
  1. 1
    Radiomics Approaches for the Prediction of Pathological Complete Response after Neoadjuvant Treatment in Locally Advanced Rectal Cancer: Ready for Prime Time?

    Radiomics Approaches for the Prediction of Pathological Complete Response after Neoadjuvant Treatment in Locally Advanced Rectal Cancer: Ready for Prime Time? by Vincent Bourbonne, Ulrike Schick, Olivier Pradier, Dimitris Visvikis, Jean‐Philippe Metges, Bogdan Badic

    Published 2023
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer

    p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer by Constantino Fondevila, Jean Philippe Metges, Josep Fuster, J.J. Grau, Antonio Palacı́n, Antoni Castells, A Volant, Manuel Pera

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Intratumor Heterogeneity Characterized by Textural Features on Baseline <sup>18</sup>F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal Cancer

    Intratumor Heterogeneity Characterized by Textural Features on Baseline <sup>18</sup>F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal Cancer by Florent Tixier, Catherine Cheze Le Rest, Mathieu Hatt, N. Albarghach, Olivier Pradier, Jean‐Philippe Metges, Laurent Corcos, Dimitris Visvikis

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Reproducibility of <sup>18</sup>F-FDG and 3′-Deoxy-3′-<sup>18</sup>F-Fluorothymidine PET Tumor Volume Measurements

    Reproducibility of <sup>18</sup>F-FDG and 3′-Deoxy-3′-<sup>18</sup>F-Fluorothymidine PET Tumor Volume Measurements by Mathieu Hatt, Catherine Cheze‐Le Rest, Eric O. Aboagye, Laura Kenny, Lula Rosso, Federico Turkheimer, N. Albarghach, Jean‐Philippe Metges, Olivier Pradier, Dimitris Visvikis

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

    Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial by Sophie Cousin, Coralie Cantarel, Jean‐Philippe Guégan, Carlos Gomez‐Roca, Jean‐Philippe Metges, Antoine Adenis, Simon Pernot, C. Bellera, Michèle Kind, Céline Auzanneau, François Le Loarer, Isabelle Soubeyran, Alban Bessede, Antoîne Italiano

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study

    Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study by Michel Ducreux, Lone Nørgård Pétersen, Leopold Öhler, Francesca Bergamo, Jean‐Philippe Metges, Jan Willem de Groot, Jaw‐Yuan Wang, Beatriz Paredes, Emmanuelle Dochy, Sabine Fiala-Buskies, Andrés Cervantes, Juan Manuel O’Connor, Alfredo Falcone

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial

    Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial by Alice Boilève, Marc Hilmi, Paul Gougis, Romain Cohen, Benoı̂t Rousseau, Jean‐Frédéric Blanc, Méher Ben Abdelghani, Hélène Castanie, Laëtitia Dahan, David Tougeron, Jean‐Philippe Metges, Christophe Tournigand, Marie‐Line Garcia‐Larnicol, Déwi Vernerey, Anthony Turpin, Cindy Neuzillet

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181

    Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181 by Antoine Adenis, Amit S. Kulkarni, Gustavo Girotto, Christelle de la Fouchardière, Hélène Senellart, Hanneke W. M. van Laarhoven, Wasat Mansoor, Raed Moh’d Taiseer Al-Rajabi, Josephine M. Norquist, Mayur M. Amonkar, Shailaja Suryawanshi, Pooja Bhagia, Jean‐Philippe Metges

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma

    ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma by Samuel J. Klempner, Keun‐Wook Lee, Kohei Shitara, Jean‐Philippe Metges, Sara Lonardi, David H. Ilson, Nicola Fazio, Tae‐Yong Kim, Li‐Yuan Bai, Diarmuid Moran, Jianning Yang, Ahsan M. Arozullah, Jung Wook Park, Jeffrey J. Raizer, Yung‐Jue Bang, Manish A. Shah

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival

    Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival by Manish A. Shah, David Cunningham, Jean‐Philippe Metges, Eric Van Cutsem, Zev A. Wainberg, Emon Elboudwarej, Kai-Wen Lin, Scott Turner, Marianna Zavodovskaya, David Inzunza, Jinfeng Liu, Scott D. Patterson, Jingzhu Zhou, Jing He, Dung Thai, Pankaj Bhargava, Carrie Baker Brachmann, Daniel V T Cantenacci

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics

    Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma pr... by Sophie Cousin, Jean-Philippe Guégan, Kohei Shitara, Lola‐Jade Palmieri, Jean Philippe Metges, Simon Pernot, Shota Fukuoka, Shohei Koyama, Hiroyoshi Nishikawa, C. Bellera, Antoine Adenis, Carlos Gomez‐Roca, Philippe A. Cassier, Antoine Hollebecque, Coralie Cantarel, Michèle Kind, Isabelle Soubeyran, Lucile Vanhersecke, Alban Bessede, Antoîne Italiano

    Published 2024
    Get full text
    Carta
    Save to List
    Saved in:
  12. 12
    Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial

    Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial by Pascal Hammel, Fabienne Portales, Laurent Mineur, Jean‐Philippe Metges, Thierry André, Christelle de la Fouchardière, Christophe Louvet, Farid El Hajbi, Roger Faroux, Rosine Guimbaud, David Tougeron, Olivier Bouché, Thierry Lecomte, Christine Rebischung, Christophe Tournigand, Jérôme Cros, Richard Kay, Adam Hamm, Anu Gupta, Jean‐Baptiste Bachet, Iman El Hariry

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)

    Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multic... by Thierry Lecomte, Bruno Giraudeau, Jean-Marc Phelip, Christophe Tournigand, Michel Ducreux, David Tougeron, Côme Lepage, Laurent Mineur, Philippe Laplaige, Romain Desgrippes, Pascal Artru, Christophe Borg, Marine Jary, Olivier Bouché, Jean‐Philippe Metges, Rosine Guimbaud, Thomas Aparicio, Fanny Foubert, Vincent Hautefeuille, Marie Müller, Karine Bouhier‐Leporrier, Rémi Darrius, Sarah Lobet, Fanny Monmousseau, Théodora Bejan‐Angoulvant, Gilles Paintaud, David Ternant

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

    Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer by Takashi Kojima, Manish A. Shah, Kei Muro, Éric François, Antoine Adenis, Chih‐Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung‐Bae Kim, Se‐Hoon Lee, Jaafar Bennouna, Ken Kato, Lin Shen, Peter C. Enzinger, Shukui Qin, P. Ferreira, Jia Chen, Gustavo Girotto, Christelle de la Fouchardière, Hélène Senellart, Raed Moh’d Taiseer Al-Rajabi, Florian Lordick, Ruixue Wang, Shailaja Suryawanshi, Pooja Bhagia, Soonmo Peter Kang, Jean‐Philippe Metges

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study

    Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study by Hugues Bourgeois, Françoise Grudé, P. Solal-Céligny, Olivier Dupuis, Éric Voog, G. Ganem, Fabrice Denis, M. Zinger, Laurence Juhel-Voog, C. Lafond, P. Maillart, Olivier Capitain, R. Delva, P Soulié, Sophie Abadie‐Lacourtoisie, Véronique Guerin‐Meyer, Marie-Emmanuelle Morin-Meschin, Jean‐Marie Commer, A. Gangler, Bénédicte d’Aillières, Alain Zannetti, Emmanuelle Bourbouloux, D. Berton-Rigault, Sophie Lebouvier-Sadot, Mehdi Kaassis, J Baudon, You Heng Lam, A. Bizieux, M. Marcq, Julien Edeline, Fanny Le Du, Claudia Lefeuvre, Philippe Deguiral, Valérie Delecroix, Emmanuel Blot, Joëlle Egreteau, M.-J. Goudier, R. Lamy, Marc Ferec, Xavier Artignan, Stéphane Corbinais, Hugues Morel, Anne Claire Hardy-Bessard, Caroline Alleaume, Emmanuel Naudeix, Oana Cojocarasu, Jean‐Philippe Metges, C. Riché, Érick Gamelin, Delphine Déniel-Lagadec, Fanny Marhuenda, Pierre Ingrand, Jean‐Yves Douillard

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

    Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study by James J. Harding, Jia Fan, Do‐Youn Oh, Hye Jin Choi, Jin Won Kim, Heung-Moon Chang, Lequn Bao, Hui‐Chuan Sun, Teresa Macarulla, Feng Xie, Jean‐Philippe Metges, Jieer Ying, John Bridgewater, Myung Ah Lee, Mohamedtaki Abdulaziz Tejani, Emerson Y. Chen, Dong Uk Kim, Harpreet Wasan, Michel Ducreux, Yuanyuan Bao, Lisa Boyken, Jiafang Ma, Phillip M. Garfin, Shubham Pant, Ghassan K. Abou‐Alfa, J. Adeva Alfonso, Massimo Aglietta, Ari David Baron, Muhammad Shaalan Beg, Paula Carrasco Aguirre, Eric X. Chen, Ying Cheng, Antonio Cubillo Gracián, Laëtitia Dahan, Filippo de Braud, Elisabetta Fenocchio, Olumide Gbolohon, Roopinder Gillmore, Marine Jary, Milind Javle, Yixing Jiang, Jung Hun Kang, Gentry George King, Madappa N. Kundranda, Laura Layos, Daneng Li, Tingbo Liang, Sara Lonardi, Omkar Marathe, Sebastián Mondaca, Andrés J. Muñoz Martín, Joon Oh Park, Roberto Pazo-Cid, Paula Ribera Fernandez, Lorenza Rimassa, Rosa Alonso, Saeed Sadeghi, Aaron J. Scott, Benjamin Tan, David Tougeron, Qiang Yan, Xiaoyu Yin, Haitao Zhao

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: